Not Signed In -
Movement Disorders |
Dyskinesia |
Clinical Trial: Treatment of Parkinson's Disease with Eliprodil
This study has been completed.
|
Purpose
Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped posture, and a shuffling-type walk (gait).
In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that are associated with the symptoms of Parkinson's Disease.
| Condition | Phase |
|---|---|
| Movement Disorders Parkinson Disease | Phase II |
MedlinePlus related topics: Movement Disorders; Parkinson's Disease
Genetics Home Reference related topics: Parkinson disease
Study Type: Interventional
Study Design: Treatment, Safety/Efficacy
Official Title: NMDA-Receptor Blockade with Eliprodil in Parkinson's Disease
Expected Total Enrollment: 20
Study start: March 26, 1999; Study completion: January 17, 2001
The objectives of this study are to evaluate the acute effects of the NR2B subtype-selective NMDA antagonist eliprodil on levodopa-associated motor response complications in patients with advanced Parkinson's Disease (PD).
Eligibility
Genders Eligible for Study: Both
Criteria
Males and females between the ages of 18-75.
No presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk.
No patients with baseline QTc prolongation (greater than 440 msec).
No pregnant women nor those not practicing effective means of birth control.
Location Information
Maryland
National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
More Information
Publications
Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990 Sep 21;249(4975):1436-8.
Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 1989;32(1):213-26.
Record last reviewed: January 4, 2000
Last Updated: December 11, 2002
Record first received: November 3, 1999
ClinicalTrials.gov Identifier: NCT00001929
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Angelman Syndrome (National Institute of Neurological Disorders and Stroke)
- Angelman Syndrome (Angelman Syndrome Foundation)
email this page
print this page
bookmark this page
feedback on this page
